The Leukemia & Lymphoma Society (LLS) will present new data from its Beat AML® Master Clinical Trial and Pediatric Acute Leukemia (PedAL) ...

Cesar Rodriguez, MD, discussed several key aspects of talquetamab use in the treatment of relapsed/refractory multiple ...

The Connecticut resident said she’s a woman of strong faith who believes in the power of prayer and that’s all that helped to ...

The key secondary end point of overall survival (OS) was met in the DREAMM-7 trial of belantamab mafodotin (Blenrep; GSK) for the treatment of patients with relapsed/refractory multiple myeloma (R/R ...

This important study identifies the "H-state" as a potential conformational marker distinguishing amyloidogenic from non-amyloidogenic light chains, addressing a critical problem in protein misfolding ...

Researchers sought to better understand the experiences of patients living with multiple myeloma and their perceptions of palliative care.

Patients with relapsed/refractory multiple myeloma could benefit from repeat treatment with drugs their disease has ...

"MRD testing has revolutionized our approach to multiple myeloma, allowing us to detect even the smallest traces of cancer ...

Brian Griffin has incurable blood cancer and, while he is well enough at the moment after a second and final stem cell ...

Findings from a phase 3 trial with Blenrep, Velcade and dexamethasone in relapsed/refractory multiple myeloma will be ...